PL377931A1 - Farmaceutyczne preparaty donosowe oraz sposoby ich stosowania - Google Patents

Farmaceutyczne preparaty donosowe oraz sposoby ich stosowania

Info

Publication number
PL377931A1
PL377931A1 PL377931A PL37793104A PL377931A1 PL 377931 A1 PL377931 A1 PL 377931A1 PL 377931 A PL377931 A PL 377931A PL 37793104 A PL37793104 A PL 37793104A PL 377931 A1 PL377931 A1 PL 377931A1
Authority
PL
Poland
Prior art keywords
methods
same
pharmaceutical formulations
nasal pharmaceutical
nasal
Prior art date
Application number
PL377931A
Other languages
English (en)
Other versions
PL208784B1 (pl
Inventor
Imtiaz Chaudry
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PL377931A1 publication Critical patent/PL377931A1/pl
Publication of PL208784B1 publication Critical patent/PL208784B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0029—Radiation
    • A61L2/0035—Gamma radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL377931A 2003-04-16 2004-03-29 Farmaceutyczny, a zwłaszcza wodny aerozolowy preparat donosowy, zestaw farmaceutyczny zawierający taki preparat oraz zastosowanie beklometazonu do jego wytwarzania PL208784B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/414,682 US9808471B2 (en) 2003-04-16 2003-04-16 Nasal pharmaceutical formulations and methods of using the same

Publications (2)

Publication Number Publication Date
PL377931A1 true PL377931A1 (pl) 2006-02-20
PL208784B1 PL208784B1 (pl) 2011-06-30

Family

ID=33158745

Family Applications (2)

Application Number Title Priority Date Filing Date
PL377854A PL222060B1 (pl) 2003-04-16 2004-03-29 Farmaceutyczne preparaty donosowe oraz sposoby ich stosowania
PL377931A PL208784B1 (pl) 2003-04-16 2004-03-29 Farmaceutyczny, a zwłaszcza wodny aerozolowy preparat donosowy, zestaw farmaceutyczny zawierający taki preparat oraz zastosowanie beklometazonu do jego wytwarzania

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL377854A PL222060B1 (pl) 2003-04-16 2004-03-29 Farmaceutyczne preparaty donosowe oraz sposoby ich stosowania

Country Status (15)

Country Link
US (3) US9808471B2 (pl)
EP (1) EP1613280B1 (pl)
JP (1) JP4680180B2 (pl)
KR (1) KR101312311B1 (pl)
CN (3) CN1805730A (pl)
AU (2) AU2004229147A1 (pl)
BR (1) BRPI0409381A (pl)
CA (1) CA2522292C (pl)
ES (1) ES2643077T3 (pl)
HK (1) HK1164133A1 (pl)
MX (1) MXPA05011107A (pl)
PL (2) PL222060B1 (pl)
RU (1) RU2380090C2 (pl)
WO (1) WO2004091574A1 (pl)
ZA (2) ZA200509239B (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US7811606B2 (en) * 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
EP2486942B1 (en) 2004-11-24 2018-10-10 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
JP4778053B2 (ja) 2005-07-14 2011-09-21 リセラ，インコーポレイテッド 局所的脂肪組織処置のための徐放性増強脂肪分解処方物
TWI345681B (en) * 2006-02-08 2011-07-21 Showa Denko Kk Antistatic agent, antistatic film and articles coated with antistatic film
PL2077830T3 (pl) * 2006-10-17 2013-04-30 Lithera Inc Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej
CN101214221A (zh) * 2007-12-27 2008-07-09 黄明 治疗鼻炎鼻窦炎药物制剂
US20090271021A1 (en) * 2008-04-28 2009-10-29 Popp Shane M Execution system for the monitoring and execution of insulin manufacture
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
GB2487868B (en) * 2010-01-15 2014-12-10 Neothetics Inc Lyophilized cake formulations
CN102166219B (zh) * 2010-05-25 2013-04-17 杭州天龙药业有限公司 一种鼻腔给药制剂及其应用
GB2485885B (en) 2010-11-24 2015-06-17 Neothetics Inc Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
DE102011103347B4 (de) * 2011-05-27 2014-10-30 Meda Pharma Gmbh & Co. Kg Nasale pharmazeutische Formulierung
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
EP2847207B1 (en) 2012-05-08 2019-03-27 Nicox Ophthalmics, Inc. Fluticasone propionate nanocrystals
CN103505412A (zh) * 2012-06-26 2014-01-15 上海臣邦医药科技有限公司 一种吸入用丙酸氟替卡松混悬液的制备方法
CN103893120A (zh) * 2012-12-27 2014-07-02 重庆华邦制药有限公司 提高了稳定性的丙酸氟替卡松喷雾剂
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US20140242040A1 (en) * 2013-02-23 2014-08-28 Stemnion, Inc. Methods for preventing and/or treating nasal polyps and rhinosinusitis
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
ES2920802T3 (es) * 2013-03-26 2022-08-09 Optinose As Administración nasal
JP6945614B2 (ja) * 2014-03-26 2021-10-06 オプティノーズ アズ 経鼻投与
MX2016017038A (es) * 2014-06-25 2017-05-01 Optinose As Administracion nasal.
US20180200206A1 (en) * 2015-07-14 2018-07-19 Atossa Genetics Inc. Transpapillary methods and compositions for treating breast disorders
CN104940994B (zh) * 2015-07-14 2017-09-19 江苏威克斯医疗科技有限公司 一种人造鼻粘膜及其用途
CN106974914B (zh) * 2017-04-28 2019-06-21 山东省千佛山医院 利奈唑胺联合氟康唑的抗真菌产品及其应用
CN107320449B (zh) * 2017-08-07 2020-09-15 武汉武药科技有限公司 丙酸氟替卡松鼻喷雾剂及其制备方法
JP7470646B2 (ja) 2018-06-14 2024-04-18 アストラゼネカ・ユーケイ・リミテッド コルチコステロイド医薬組成物を用いて喘息の症状を治療および予防するための方法
USD959279S1 (en) 2020-04-07 2022-08-02 VB Brands LLC Spray bottle
EP4135658A1 (en) * 2020-04-14 2023-02-22 GlaxoSmithKline Consumer Healthcare Holdings (US) LLC Nasal spray formulation with moisturizing benefits

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2989437A (en) 1955-06-08 1961-06-20 Upjohn Co Anti-inflammatory and anti-bacterial decongestant nasal spray compositions
US3091569A (en) 1960-08-26 1963-05-28 Mead Johnson & Co Mucolytic-nu-acylated sulfhydryl compositions and process for treating animal mucus
GB2107715B (en) 1981-10-19 1985-11-13 Glaxo Group Ltd Micronised beclomethasone dipropionate monohydrate and powder inhalation compositions containing it
GB8432063D0 (en) 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids
EP0302595B1 (en) 1987-07-07 1994-02-02 Beecham Group Plc Pinacidil for treatment of pulmonary hypertension or right heart failure
AU610175B2 (en) 1988-05-25 1991-05-16 Biogal Gyogyszergyar Pharmaceutical composition comprising a compound containing sulfhydryl group(s) for the treatment of otitis
CA2010894A1 (en) 1989-02-28 1990-08-31 Isamu Horikoshi Method of forming a suspension and composition formed by said method
JPH03165833A (ja) 1989-02-28 1991-07-17 Isamu Horikoshi 新規懸濁化方法及びこの方法によって得られる組成物
SE9000207L (sv) 1990-01-22 1991-07-23 Nobel Chemicals Ab Laekemedel samt anvaendningen av detsamma
WO1992004365A1 (en) 1990-09-10 1992-03-19 Schering Corporation Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
US5174475A (en) 1991-03-26 1992-12-29 Glaxo Inc. Sequential dosing of antifungal and antiinflammatory compositions
US5593688A (en) 1993-06-25 1997-01-14 Nexstar Pharmaceuticals, Inc. Liposomal targeting of ischemic tissue
JPH0753358A (ja) 1993-08-17 1995-02-28 Teijin Ltd 吸入剤
GB9410222D0 (en) 1994-05-21 1994-07-06 Glaxo Wellcome Australia Ltd Medicaments
US6113894A (en) 1995-01-23 2000-09-05 Smith; S. Gregory Ophthalmic compositions and process of using
IT1275955B1 (it) 1995-03-22 1997-10-24 Dompe Spa Formulazioni farmaceutiche in forma di gel tissotropico
AU7106996A (en) 1995-09-07 1997-03-27 Fuisz Technologies Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
US5958378A (en) 1996-07-03 1999-09-28 Research Development Foundation High dose liposomal aerosol formulations containing cyclosporin A or budesonide
TW416953B (en) 1996-09-25 2001-01-01 Takeda Chemical Industries Ltd Tricyclic compounds for eliciting a prostaglandin I2 receptor agonistic effect, their production and use
FR2756739B1 (fr) 1996-12-05 2000-04-28 Astra Ab Nouvelle formulation de budesonide
DE19653969A1 (de) 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
TW503113B (en) 1997-01-16 2002-09-21 Senju Pharma Co Aqueous suspension for nasal administration
US5828330A (en) * 1997-03-19 1998-10-27 Exar Corporation Analog to digital converter having dynamically controlled non-linear output
ATE216244T1 (de) 1997-10-09 2002-05-15 Schering Corp Mometasonfuroat-suspensionen zum zerstäuben
BR9814615A (pt) 1997-10-22 2001-10-16 Jens Ponikau Métodos e materiais para o tratamento e prevenção de inflamação do tecido da mucosa
JP3386349B2 (ja) 1997-10-30 2003-03-17 帝人株式会社 水性懸濁医薬品組成物
SE9704186D0 (sv) 1997-11-14 1997-11-14 Astra Ab New composition of matter
US6423423B2 (en) 1998-05-06 2002-07-23 Calsonic Kansei Corporation Formed strip and roll forming
US6241969B1 (en) 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
WO2000012063A1 (fr) 1998-08-26 2000-03-09 Teijin Limited Compositions en poudre s'administrant par voie nasale
IT1303692B1 (it) 1998-11-03 2001-02-23 Chiesi Farma Spa Procedimento per la preparazione di sospensioni di particelle difarmaci da somministrare per inalazione.
US20040141925A1 (en) 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6521212B1 (en) 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
CN1319020A (zh) 1999-06-03 2001-10-24 约翰逊及约翰逊法国消费者有限公司 抗炎症性疾病的野甘菊提取物
JP2001002589A (ja) 1999-06-18 2001-01-09 Teijin Ltd 穏やかな薬物血中濃度の上昇を可能とする経鼻投与用組成物
US20020061281A1 (en) 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
AU6076200A (en) 1999-07-08 2001-01-30 Johnson & Johnson Consumer Companies, Inc. Exothermic bandage
GB9918559D0 (en) 1999-08-07 1999-10-06 Glaxo Wellcome Kk Novel pharmaceutical formulation
WO2001013885A1 (en) 1999-08-20 2001-03-01 Norton Healthcare Ltd. Method to produce powders for pulmonary or nasal administration
GB9925934D0 (en) 1999-11-03 1999-12-29 Glaxo Group Ltd Novel apparatus and process
FI20002217A (fi) 1999-12-30 2001-07-01 Orion Yhtymae Oyj Inhalaatiopartikkelit
GB0009605D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Medicaments
US20020013331A1 (en) 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
GB0016040D0 (en) 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
BR0112461A (pt) 2000-07-14 2003-07-22 Allergan Inc Composições que contém componentes terapeuticamente ativos tendo uma solubilidade aumentada
US7141236B2 (en) * 2000-07-28 2006-11-28 Nektar Therapeutics Methods and compositions for delivering macromolecules to or via the respiratory tract
US6608054B2 (en) * 2001-03-20 2003-08-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and endothelin antagonists
CA2436814A1 (en) 2000-12-01 2002-07-18 Nephros Therapeutics, Inc. Intravascular drug delivery device and use therefor
DE10060890C2 (de) 2000-12-07 2003-04-03 Meta Motoren Energietech Vorrichtung zum Umschalten des Betriebs eines Ladungswechselventils einer Brennkraftmaschine
US20020132803A1 (en) 2001-01-05 2002-09-19 Mahendra Dedhiya Fluticasone suspension formulation, spray pattern method, and nasal spray apparatus
JP2004520432A (ja) 2001-02-05 2004-07-08 ファルマシア・アンド・アップジョン・カンパニー オキサゾリジノン抗菌薬の直腸送達のための組成物
GB0105560D0 (en) 2001-03-07 2001-04-25 Glaxo Group Ltd Pharmaceutical formulations
JP4634694B2 (ja) 2001-03-23 2011-02-16 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド 脂肪アルコール薬物複合体
WO2002076402A2 (en) 2001-03-23 2002-10-03 Protarga, Inc. Fatty amine drug conjugates
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
WO2003013434A2 (en) 2001-08-06 2003-02-20 Genomed, Llc Methods and compositions for treating diseases associated with excesses in ace
FR2831446B1 (fr) 2001-10-26 2004-03-05 Sanofi Synthelabo Utilisation de l'irbesartan pour la preparation de medicaments utiles pour la prevention ou le traitement de l'hypertension pulmonaire
KR20030045246A (ko) 2001-12-01 2003-06-11 엘지전자 주식회사 휴대용 단말기의 특정 기능 실행 방법 및 장치
US7008644B2 (en) 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
ITMI20022674A1 (it) 2002-12-18 2004-06-19 Chiesi Farma Spa Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
US20040208833A1 (en) 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US9808471B2 (en) 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US7811606B2 (en) 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis

Also Published As

Publication number Publication date
BRPI0409381A (pt) 2006-04-18
ES2643077T3 (es) 2017-11-21
US7972626B2 (en) 2011-07-05
AU2004229147A1 (en) 2004-10-28
RU2005135335A (ru) 2006-05-10
WO2004091574A1 (en) 2004-10-28
KR101312311B1 (ko) 2013-10-10
CN1805730A (zh) 2006-07-19
JP4680180B2 (ja) 2011-05-11
EP1613280B1 (en) 2017-07-12
US20040208830A1 (en) 2004-10-21
EP1613280A1 (en) 2006-01-11
MXPA05011107A (es) 2006-05-19
HK1164133A1 (en) 2012-09-21
CA2522292C (en) 2011-11-08
CN1774238B (zh) 2013-09-04
ZA200509240B (en) 2007-04-25
PL208784B1 (pl) 2011-06-30
CN102319209A (zh) 2012-01-18
US9808471B2 (en) 2017-11-07
ZA200509239B (en) 2007-04-25
KR20060003010A (ko) 2006-01-09
CA2522292A1 (en) 2004-10-28
US20080050442A1 (en) 2008-02-28
US20060051299A1 (en) 2006-03-09
AU2010203026A1 (en) 2010-08-05
PL377854A1 (pl) 2006-02-20
RU2380090C2 (ru) 2010-01-27
PL222060B1 (pl) 2016-06-30
CN102319209B (zh) 2013-09-04
JP2006523630A (ja) 2006-10-19
CN1774238A (zh) 2006-05-17
AU2010203026B2 (en) 2012-07-05

Similar Documents

Publication Publication Date Title
HK1164133A1 (en) Nasal pharmaceutical formulations and methods of using the same
HK1091727A1 (en) Nasal pharmaceutical formulations and methods of using the same
HK1084883A1 (en) 2-cyanopyrrolopyrimidines and pharmaceutical uses thereof
IL176248A0 (en) N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof
EP1367060A4 (en) GLUCOPYRANOSYLOXYBENZYLBENZENE DERIVATIVES AND THEIR MEDICAL USE
EP1364957A4 (en) GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND THEIR MEDICAL USE
EP1364958A4 (en) GLYCOPYRANOSYLOXYPYRAZOLE DERIVATIVES AND MEDICINAL USE THEREOF
GB0210397D0 (en) Pharmaceutical formulations
HK1078086A1 (zh) 雜芳族五環化合物及其醫藥用途
EP1479666A4 (en) ESTER CONNECTION AND THEIR MEDICAL USE
EP1838291A4 (en) PHARMACEUTICAL FORMULATIONS AND METHOD OF USE THEREOF
IL176384A (en) Pyrrolidinochlorinated basazole and pharmacy preparations containing them
IL170313A (en) Diarylcycloalkyl derivatives and pharmaceutical compositions comprising them
EP1646355A4 (en) PHARMACEUTICAL FORMULATIONS
IL163868A (en) Hemiasterlin derivatives and pharmaceutical compositions comprising them
GB0108470D0 (en) Pharmaceutical compositions and their use
GB2392093B (en) Pharmaceutical formulations
IL162937A0 (en) Pravastatin pharmaceutical formulations and methods of their use
GB0202900D0 (en) Novel formulations of drugs
GB0302672D0 (en) Pharmaceutical formulations
IL175746A0 (en) Oral formulations of desoxypeganine and uses thereof
AU2002359618A1 (en) Medicinal compositions and therapeutic methods
IL149377A0 (en) Pharmaceutical formulation comprising melatonin
EP1622623A4 (en) METHOD FOR THE ADMINISTRATION OF ESTROGENIC AND TESTED
GB0316341D0 (en) Pharmaceutical formulations